We are live on ! Find out more
FTH

Faeth Therapeutics
FTH

24 hedge funds and large institutions have $3.58M invested in Faeth Therapeutics in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.09% more ownership

Funds ownership: 0.51% → 0.59% (+0.09%)

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

8% less funds holding

Funds holding: 26 → 24 (-2)

24% less capital invested

Capital invested by funds: $4.71M → $3.58M (-$1.12M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
24
Holders Change
-2
Holders Change %
-7.69%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
6
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$419K
2
TRCT
Tower Research Capital (TRC)
New York
+$8.08K
3
UBS Group
UBS Group
Switzerland
+$4.51K
4
Bank of America
Bank of America
North Carolina
+$1.17K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$615

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$188K
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$136K
3
Renaissance Technologies
Renaissance Technologies
New York
-$52.3K
4
Millennium Management
Millennium Management
New York
-$23.4K
5
E
Ergoteles
New York
-$23.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
NM
1
Newtyn Management
New York
$2.08M +$419K +14,316 +19%
Vanguard Group
2
Vanguard Group
Pennsylvania
$654K – – –
BCM
3
Bridgeway Capital Management
Texas
$129K – – –
DFO
4
Duquesne Family Office
New York
$114K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$112K – – –
Bank of America
6
Bank of America
North Carolina
$103K +$1.17K +40 +0.9%
Renaissance Technologies
7
Renaissance Technologies
New York
$102K -$52.3K -1,785 -29%
Millennium Management
8
Millennium Management
New York
$61.8K -$23.4K -799 -23%
BlackRock
9
BlackRock
New York
$41.8K -$2.11K -72 -4%
Northern Trust
10
Northern Trust
Illinois
$29.7K – – –
State Street
11
State Street
Massachusetts
$29.4K – – –
Two Sigma Advisers
12
Two Sigma Advisers
New York
$28.4K -$2.05K -70 -5%
LB
13
Leo Brokerage
Texas
$16.9K – – –
RJA
14
Raymond James & Associates
Florida
$16K – – –
Two Sigma Investments
15
Two Sigma Investments
New York
$15.5K -$2.49K -85 -11%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$13.2K – – –
DCM
17
Deuterium Capital Management
Florida
$12.5K – – –
TRCT
18
Tower Research Capital (TRC)
New York
$8.52K +$8.08K +276 +282%
UBS Group
19
UBS Group
Switzerland
$7.42K +$4.51K +154 +90%
BCV
20
Banque Cantonale Vaudoise
Switzerland
$4K – – –
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
$1K +$615 +21 +700%
JP Morgan Chase
22
JP Morgan Chase
New York
$762 – – –
Morgan Stanley
23
Morgan Stanley
New York
$250 -$188K -6,421 -100%
Wells Fargo
24
Wells Fargo
California
$150 +$29 +1 +17%
Fidelity Investments
25
Fidelity Investments
Massachusetts
$9 – – –
1
2

FTH Hedge Fund Activity: Q2 2023 in Review

24 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q2 2023, worth a combined $3.58M — down 24% from $4.71M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of FTH and 0 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 6 added.

The largest buyer was Newtyn Management, adding an estimated $419K. The largest seller was Morgan Stanley, cutting an estimated $188K.

  • 24 institutional investors held Faeth Therapeutics (FTH) as of Q2 2023, down from 26 in Q1 2023.
  • Funds reported $3.58M of Faeth Therapeutics stock for Q2 2023, down 24% quarter-over-quarter.
  • 0 funds opened new Faeth Therapeutics positions in Q2 2023 and 2 closed out, a net change of -2 holders.
  • The largest Faeth Therapeutics buyer in Q2 2023 was Newtyn Management, an estimated $419K added.
  • The largest Faeth Therapeutics seller in Q2 2023 was Morgan Stanley, an estimated $188K sold.

Based on aggregated 13F filings for Q2 2023.